• Explore /
  • Poster
  • / A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.

A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.

Abstract Poster

Authors

Howard Burris, III

Howard A. Burris III

Sarah Cannon Research Institute, Nashville, TN

Howard A. Burris III, Minal A. Barve , Erika Paige Hamilton , Aditya Bardia , Hatem Hussein Soliman , Donna Jarlenski , Rebecca Mosher , Donald Alan Bergstrom

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Immunoconjugates

Clinical Trial Registration Number

NCT02952729

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS2606)

DOI

10.1200/JCO.2017.35.15_suppl.TPS2606

Abstract #

TPS2606

Poster Bd #

93a

Abstract Disclosures

Similar Posters

First Author: Sara A. Hurvitz

First Author: Alexios Matikas

First Author: Hope S. Rugo

First Author: Erika Paige Hamilton